Compare Crispr Therapeutics AG (CRSP) vs Garmin Ltd. (GRMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Garmin Ltd. — how do they compare? Crispr Therapeutics AG trades at $53.89 (market cap $5.23B), while Garmin Ltd. trades at $310.33 (market cap $59.72B). The key difference: Garmin Ltd. is far larger — about 11.4× Crispr Therapeutics AG's market cap, and Garmin Ltd. pays a 1.36% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | GRMN | |
|---|---|---|
Market Cap | $5.23B | $59.72B |
Sector | Health | Technology |
52-Week High | $76.78 | $313.16 |
52-Week Low | $44.34 | $187.10 |
Enterprise Value | $3.65B | $57.23B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Garmin (GRMN) trades at $313.16, up 0.73% on the day and near its all-time high, with a bullish technical trend and strong support at $309. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.81 beating estimates of $2.30, and raised full-year guidance. Revenue growth accelerated to 11% in Q2 2026, driven by strong performance in the fitness segment, while net income margin improved to 24.47%.
The outlook remains positive given robust fundamentals and raised guidance, but risks include rich valuation multiples, potential growth deceleration, and insider selling. Analyst consensus is cautious with a hold-heavy rating, though the average price target of $318.67 suggests modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
